Considering the critical role of HTATIP2 in the suppression of HCC growth and metastasis and the inhibition of proangiogenic capability of the tumor cells, we speculated that the invasive and metastatic potential of residual tumor cells with high HTATIP2 expression would be stimulated after downregulation of HTATIP2 expression following sorafenib treatment. The gene discussed is HTATIP2; the disease is neoplasm.